Fat intake has long been associated with the development of obesity. The studies described herein show that fat adversely affects adipocyte adrenergic receptor (AR) expression and function. As ␤ 3 AR agonists have been shown to acutely reduce adipose tissue mass and improve thermogenesis in genetically obese rodents, we examined whether chronic supplementation of a high fat diet with a highly selective ␤ 3 AR agonist, CL316,243, could prevent diet-induced obesity, and whether the effect could be sustained over prolonged treatment. C57BL/6J and A/J mice were weaned onto one of three diets: low fat (10.5% calories from fat), high fat (58% calories from fat), or high fat supplemented with 0.001% CL316,243. B/6J mice gained more weight on the high fat diet than A/J mice (at 16 weeks: B/6J, 36.6 Ϯ 1.4 g; A/J, 32.9 Ϯ 0.8 g; P Ͻ 0.002; n ϭ 10), whereas weights on the low fat diets were similar (B/6J, 29.5 Ϯ 0.5 g; A/J, 28.8 Ϯ 0.6 g; P Ͼ 0.05; n ϭ 10). CL316,243 prevented the development of dietinduced obesity in A/J animals, but not in B/6J animals. A/J mice weighed 26.0 Ϯ 0.5 g at 16 weeks, whereas B/6J animals on the same diet weighed 34.1 Ϯ 0.8 g (P Ͻ 0.00001; n ϭ 10), but food intake was not different between the strains throughout the study. ␤-Adrenergic stimulation of adenylyl cyclase in obese B/6J mice was decreased by more than 75% in white adipose tissue and by more than 90% in brown adipose tissue (BAT). In contrast, in fat-fed A/J mice, ␤-agonist-stimulated adenylyl cyclase was decreased in white adipose tissue by about 10%, whereas the activity in interscapular BAT was decreased by 50%, indicating significant retention of ␤AR-stimulated activity in A/J mice compared to B/6J mice. High fat feeding was associated with decreased expression of ␤ 3 AR and ␤ 1 AR in white adipose tissue of both strains. However, chronic CL316,243 treatment prevented both the obesity and the decline in ␤ 3 AR and ␤ 1 AR messenger RNA levels in all adipose depots from A/J mice, but not B/6J mice. As CL316,243-treated A/J mice, but not B/6J mice, also showed marked uncoupling protein expression in white adipose depots, the ability of chronic CL316,243 treatment to prevent diet-induced obesity is dependent upon the elaboration of functional BAT in these regions. (Endocrinology 138: [405][406][407][408][409][410][411][412][413] 1997) 
M
UCH OF THE animal research on the genetic and biochemical determinants of obesity has been based on a number of mutant strains of rodents, such as obese (ob/ob) and diabetic (db/db) mice and the Zucker fatty rat (1) . These animals develop severe obesity on laboratory chow, which is quite low in dietary fat (4.5% of calories from fat, according to the manufacturer, Ralston Purina). However, most human obesity is thought to occur in response to high fat diets (2, 3) . We and others have demonstrated differential weight gain in various mouse strains in response to diets rich in fat (4 -6) . One strain that is especially sensitive to the effects of diet on body weight is the C57BL/6J strain (B/6J). For example, in response to a high fat diet B/6J mice develop severe obesity, hyperglycemia, hyperinsulinemia, and increased mesenteric fat cell number, whereas another strain, A/J, tends to be more resistant (7) . Furthermore, B/6J mice become obese without eating more calories than A/J mice (7) and maintain higher physical activity levels even when obese (8) . In a similar manner, certain human populations appear to be particularly predisposed toward the development of obesity and diabetes, and these features are thought to be due at least in part to genetic factors in response to diet (9) . Considerable effort has been directed toward understanding the biochemical alterations found in adipocytes from genetically obese rodents or humans. For example, previous studies in genetically obese mice have linked poor epinephrine-stimulated triglyceride metabolism and depressed cAMP responses to obesity (10 -12) . However, these earlier studies were conducted before the knowledge that a third ␤-adrenergic receptor (␤ 3 AR) exists (13) . This third ␤AR subtype is expressed predominantly in adipocytes, unlike the ␤ 1 AR and ␤ 2 AR subtypes, which are broadly distributed in tissues throughout the body. Several genetic and biochemical studies suggest that the ␤ 3 AR plays a significant role in adipocyte metabolism. Collins et al. (14) reported that the expression and function of the ␤ 3 AR and ␤ 1 AR subtypes are significantly depressed in both white and brown adipocytes of the obese (C57BL/6J ob/ob) mouse. More recently, we found essentially identical results in the other major mouse models of congenital obesity, such as diabetic, tubby, and fat mice (Daniel, K. W., E. M. Rohlfs, and S. Collins, manuscript in preparation). The significance of these observations is that pharmacological studies have shown that all three ␤AR subtypes participate in the stimulation of lipolysis (15, 16) and are able to activate expression of the mitochondrial uncoupling protein (UCP) in brown adipocytes (17) . Thus, it is important to fully understand how all three ␤AR subtypes regulate normal adipocyte physiology and, in turn, how each of the receptor subtypes themselves is regulated at the transcriptional and functional levels in the lean and obese states.
The earliest evidence suggesting the existence of a third ␤AR subtype also indicated that such a receptor could have an important role in the regulation of body composition. These initial observations included reports that short term treatment of genetically obese (ob/ob) mice with selective ␤ 3 AR agonists could retard the progression of obesity and normalize elevated plasma glucose and insulin levels (18 -20) . Reversal of dietary obesity has also been reported in rats after a shortterm (ϳ2-week) treatment with a ␤ 3 AR agonist (21) . In the studies we report here, we examined the effects of chronic treatment with a highly selective ␤ 3 AR agonist, CL316,243, on the development of diet-induced obesity in B/6J and A/J strains of mice, and on the expression of the three ␤AR subtypes in white and brown adipose tissues (WAT and BAT, respectively) of these animals. Our results indicate a striking effect of genetic background on both the development of obesity in response to high fat feeding and the ability of ␤ 3 AR agonists to prevent it.
Materials and Methods Animals
Thirty B/6J and A/J male mice were obtained from Jackson Laboratories (Bar Harbor, ME) at 4 weeks of age. The animals were housed five per cage in a temperature-controlled room with a reverse 12-h light, 12-h dark cycle. Water was available ad libitum. Mice were fed one of three diets as follows. Ten mice from each strain were placed on a low fat/low sucrose diet (LL), a high fat/low sucrose diet (HL), or a high fat/low sucrose diet containing 0.001% CL316,243 (Wyeth-Ayerst Research, Monmet Junction, NJ). The compositions of these diets have been described previously (7) . Animals were maintained on these diets for 16 weeks. Body weights of all animals were assessed biweekly. Food intake was measured for each cage of five animals within a 24-h period once per week. Individual food intake measurements were only made at three periods during the 16 weeks of the protocol due to the stress on the animals resulting from individual housing. Caloric content of food was calculated based on 5.55 Cal/g for the high fat diets and 4.07 Cal/g for the low fat diet. Feed efficiency [(weight gained/Cal consumed) ϫ 100] was determined for each cage after 16 weeks of the respective diets. Monitoring of physical activity was also conducted at monthly intervals as previously described (8) .
Blood was collected at 4-week intervals from individual animals. Samples were obtained via retroorbital sinus puncture in nonanesthetized animals after an 8-h fast. Plasma glucose was determined using a Beckman glucose analyzer 2 (Palo Alto, CA), and plasma insulin levels were measured by double antibody RIA using rat insulin as a standard (Linco Research, St. Louis, MO).
After 16 weeks on the diets, animals were killed by decapitation, and adipose tissues were isolated from the following depots: epididymal, interscapular, sc, and perirenal. Tissues were cleaned and minced finely for preparation of total RNA or plasma membranes.
Isolation and analysis of RNA
Total cellular RNA was prepared by the cesium chloride gradient method as previously detailed (22) . For Northern blot hybridization, RNA was denatured by the glyoxal procedure, fractionated through 1.2% agarose gels, and blotted onto Biotrans nylon membranes (ICN, Irvine, CA) as previously described (23) . DNA fragments, which were used as hybridization probes, were obtained from the following sources. For the three ␤AR subtypes, fragments specific for each receptor were prepared by PCR as previously described (14) . For mitochondrial UCP, a 300-bp BglI fragment, kindly provided by Dr. Leslie P. Kozak, was used (24) . The complementary DNA fragment for the ubiquitous glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase was obtained from Clontech (Palo Alto, CA). A rat complementary DNA probe for cyclophilin was obtained from J. Douglas. Radiolabeled probes were prepared by nick translation of the purified DNA fragments in the presence of [ 32 P]deoxy-CTP to a specific activity between 3-7 ϫ 10 8 dpm/g DNA. Blots were hybridized and washed as previously described (23, 25) .
Preparation of plasma membranes and adenylyl cyclase assay
Adipose tissue was isolated from each group of animals. The tissue was pooled and minced, and then plasma membranes were prepared as previously described (14) . Adenylyl cyclase activity in these plasma membrane preparations was measured using established methods (26) , and the cAMP formed was measured by RIA (27) using a polyclonal antiserum to cAMP. The ␤-agonists (Ϫ)-epinephrine, (Ϫ)-norepinephrine, (Ϫ)-isoproterenol, and (Ϫ)-propranolol were obtained from Sigma Chemical Co. (St. Louis, MO). CL316,243 was a gift from American Cyanamid Co. Protein concentrations were determined by the method of Bradford (28) .
Data analysis
Adenylyl cyclase dose-response curves and competition binding curves were analyzed by least squares nonlinear regression. (Graphpad Prism, San Diego, CA). The best fit to a one-component vs. 2-component model was determined by an F test, and comparisons between data sets were made by ANOVA. P Ͻ 0.05 was considered significant.
Results

Body weight, and plasma glucose and insulin
Both A/J and B/6J mice gained significantly more weight when consuming a high fat diet than animals on a low fat diet ( Fig. 1 ). This increase in body weight was associated with adipocyte hypertrophy, hyperplasia, and approximately a 50% increase in their percentage of total body fat, as determined by carcass analysis and bomb calorimetry (low fat B/6J, 22.4% body fat; high fat B/6J, 36.8%; low fat A/J, 24.3%; high fat A/J, 32.5%) (7) (our unpublished observations). As we previously reported, this differential weight gain occurred despite the fact that B/6J mice did not consume more calories than A/J mice (7) and were equally as active (8) . When the selective ␤ 3 AR agonist CL316,243 was included in the high fat diet, A/J mice were completely resistant to the obesity induced by high fat feeding (Fig. 1A) . In fact, they actually weighed slightly less than low fat fed animals at most time points, despite the fact that they ate as much as or even slightly more than animals consuming the high fat diet without CL316,243 (29) . In contrast, B/6J mice appeared to be refractory to the ␤ 3 AR agonist, at least under this dietary regimen (Fig. 1B) . Furthermore, mice consuming the CL316,243 diet were no more active than those not receiving treatment (data not shown).
The ability of selective ␤ 3 AR agonists to improve insulin sensitivity and normalize obesity-related hyperglycemia in genetically obese rodents has been previously reported (18 -20) , suggesting that these agents may be effective treatments for combined obesity/diabetes complications. We found that the ability of CL316,243 to alter fasting insulin and glucose levels in A/J and B/6J mice mirrored its effect on body weights in these two strains of mice. The data presented in Fig. 2 and Table 1 illustrate these findings. For example, levels of both insulin (Table 1 ) and glucose (Fig. 2) were significantly increased in A/J and B/6J mice when they were fed a high fat diet, but both of these factors were more severely elevated in B/6J mice, confirming our previous observations (7) . However, the presence of CL316,243 in the diet was associated with significant decreases in serum insulin and glucose levels in A/J mice throughout the 16-week treatment period. By contrast, although there seemed to be some improvement in the levels of both insulin and glucose in B/6J mice during the first month of treatment with CL316,243, ultimately the hyperglycemia and hyperinsulinemia resulting from high fat feeding were not reversed.
Adipocyte ␤AR function
Plasma membranes were prepared from epididymal WAT and interscapular BAT and assayed in dose-response experiments to assess adenylyl cyclase activity. We used increasing doses of either epinephrine, which will stimulate all three ␤AR subtypes (14, 16) , or the ␤ 3 AR-specific agonist CL316,243. The results indicate that in WAT, adenylyl cyclase activity stimulated by either epinephrine or CL316,243 was significantly depressed in the high fat-fed, obesity-prone B/6J mice compared with that in the low fat-fed animals (Fig.  3) . These results are strikingly similar to our earlier findings in ob/ob mice (14) and indicate impaired function of both the ␤ 1 AR/␤ 2 AR population of receptors and the ␤ 3 AR receptors. However, in A/J mice, there was a small, but significant, decrease in ␤-agonist-stimulated adenylyl cyclase activity from WAT (Fig. 4) . The level of activity was modestly lower throughout the entire concentration range examined, and the data obtained using CL316,243 to stimulate adenylyl cyclase activity suggest that the function of the ␤ 3 AR is also slightly decreased.
Interestingly, in BAT in high fat-fed A/J and B/6J mice, ␤-agonist-stimulated adenylyl cyclase activity was altered in a manner that mirrored the extent of obesity in the two strains. Figure 5 indicates that in obese, high fat-fed, B/6J mice there was nearly a complete loss in the ability of either norepinephrine or CL316,243 to stimulate cAMP production in interscapular BAT (IBAT). In A/J mice (Fig. 6) , although there was a significant reduction in ␤-agonist-stimulated ad-FIG. 1. Effect of diets on body weight of A/J and B/6J mice. Male mice from each strain were randomly assigned at 4 weeks of age to a low fat diet (E), a high fat diet (q), or a high fat diet containing 0.001% CL316,243 (f). Animals were weighed at biweekly intervals through the 16-week period on the diets. A, A/J mice; B, B/6J mice.
FIG. 2.
Effects of diets on fasting plasma glucose levels in A/J and B/6J mice. Blood was collected from mice at 4-week intervals after their assignment to diet groups and analyzed for glucose as described in Materials and Methods. E, Low fat diet; q, high fat diet; f, high fat diet containing 0.001% CL316,243.
enylyl cyclase activity in the high fat-fed animals relative to that in the low fat-fed mice, there was, nevertheless, significant retention of activity compared with that in the fat-fed obese B/6J mice (compare Figs. 5 and 6 ). These differences in adenylyl cyclase activity between the two strains were also observed in WAT and IBAT of CL316,243-treated animals ( Figs. 7 and 8, respectively) . In both adipose depots the ␤-agonist-stimulated adenylyl cyclase activity in membranes from B/6J mice, using either epinephrine or CL316,243, was minimal compared to the results in A/J mice. It is interesting that the inability of CL316,243 to prevent obesity in the high fat-fed B/6J mice is coincident with the nearly complete absence of ␤-adrenergic responsiveness in IBAT of this strain. At this point we do not know whether this lack of ␤AR activity (particularly ␤ 3 AR function) is responsible for the inability to respond to this compound. However, preliminary data examining the effects of these diets with and without CL316,243 indicate that within the first few weeks of treatment, B/6J mice initially appear to respond to 3 . ␤-Agonist-stimulated adenylyl cyclase activity in epididymal WAT tissue membranes from B/6J mice. After the 16-week period on one of the three diets, gonadal WAT was removed, and plasma membranes were prepared as described previously (13, 39) . ␤-Agoniststimulated adenylyl cyclase activity was determined in response to increasing doses of epinephrine (A) or CL316,243 (B). q, Low fat diet; E, high fat diet.
FIG. 4.
␤-Agonist-stimulated adenylyl cyclase activity in epididymal WAT membranes from A/J mice. After the 16-week period on one of the three diets, gonadal WAT was removed, and plasma membranes were prepared as previously described (13, 39) . ␤-Agonist-stimulated adenylyl cyclase activity was determined in response to increasing doses of epinephrine (A) or CL316,243 (B). q, Low fat diet; E, high fat diet.
CL316,243, as evidenced by significant decreases in the weights of selected fat pads (our unpublished observations). Additional studies are in progress to assess in greater detail the time course of body and adipose depot weights, body composition, and expression and function of ␤ARs over this chronic treatment regimen. To determine whether the observed changes in ␤-adrenergic function in adipose tissue are accompanied by alterations in the expression of the three ␤AR subtypes, we performed Northern blot analysis. Four adipose tissue depots were examined: gonadal, interscapular, sc, and perirenal. Figure 9 displays representative Northern blots from A/J mice, and Figs. 10 and 11 present quantitative comparisons between A/J and B/6J mice. The results indicate that excess adipose tissue mass due to high fat feeding is associated with decreased expression of ␤ 1 AR and ␤ 3 AR in WAT depots of both A/J and B/6J mice, whereas in IBAT of high fat-fed mice, we actually observed a slight increase in ␤ 3 AR messenger RNA (mRNA) levels. The paradoxical decrease in ␤ 3 AR mRNA levels during treatment with CL316,243 may be related to earlier studies by Granneman and colleagues (30), in which they found that cold exposure (i.e. induction of active thermogenesis) led to a decrease in ␤ 3 AR mRNA in IBAT. Therefore, at least in IBAT, the relationship among ␤ 3 AR transcripts, functional ␤ 3 ARs, and thermogenic activity will require additional study.
Regulation of brown adipocyte UCP
The ability of IBAT to modulate body composition through its capacity to thermogenically transform caloric energy into heat has been demonstrated by several investigators (31) (32) (33) . The brown adipocyte-specific UCP is largely responsible for this metabolic activity. As expression of UCP is specific for brown adipocytes, it serves as a marker for the presence and thermogenic activity of IBAT. We examined how the expression of UCP was affected in various adipose tissue depots in A/J and B/6J mice consuming the high fat diet with and without the ␤ 3 AR agonist. As shown in Figs. 9 and 12 , levels of UCP mRNA in IBAT were not significantly reduced in either A/J or B/6J mice made obese by high fat feeding. However, in the perirenal depot, which consists of a mixture of white and brown adipocytes, there were significant de-FIG. 5. ␤-Agonist-stimulated adenylyl cyclase activity in BAT membranes from B/6J mice. After the 16-week period on one of the three diets, IBAT was removed, and plasma membranes were prepared as previously described (13, 39) . ␤-Agonist-stimulated adenylyl cyclase activity was determined in response to increasing doses of epinephrine (A) or CL316,243 (B). q, Low fat diet; E, high fat diet.
FIG. 6. ␤-Agonist-stimulated adenylyl cyclase activity in BAT membranes from A/J mice. After the 16-week period on one of the diets, IBAT was removed, and plasma membranes were prepared as previously described (13, 39) . ␤-Agonist-stimulated adenylyl cyclase activity was determined in response to increasing doses of epinephrine (A) or CL316,243 (B). q, Low fat diet; E, high fat diet.
creases in UCP expression in the high fat-fed, obese animals of both strains. Of particular note, when the high fat diet was supplemented with the ␤ 3 AR agonist, CL316,243, UCP mRNA levels were significantly elevated in the interscapular depot of both A/J and B/6J mice. Moreover, in perirenal adipose tissue of A/J mice, but not in B/6J mice, UCP expression was completely restored. Most significantly, the sc and gonadal white adipose depots from A/J mice consuming the ␤ 3 AR agonist contained substantial quantitites of UCP mRNA (Fig. 9) . As there was little or no UCP in these depots in lean, low fat-fed animals, these data suggest that the ability of CL316,243 to prevent obesity in A/J mice is related to increased thermogenic activity in these peripheral depots as well as in the major interscapular BAT depot. Consistent with this interpretation, preliminary histological studies show that A/J mice treated with CL316,243 displayed marked increases in brown adipocytes that express immunoreactive UCP in several depots, including perirenal, retroperitoneal, and gonadal (our unpublished observations).
Discussion
These data are the first demonstration that high fat feeding can adversely affect adipocyte AR expression and function. Furthermore, these effects are dependent upon genetic background and are correlated with the effects of a high fat diet on obesity and glucose metabolism. Epidemiological studies have long shown that fat intake is predictive of obesity and diabetes (2, 3) . Although it has been widely assumed that these effects of fat are due simply to the increased caloric density of a high fat diet, our data offer an additional mechanism by which dietary fat interacts with unknown genetic factors to decrease both lipid mobilization in WAT and thermogenic activity in BAT. We found that both strains show depressed adipocyte ␤AR function, particularly in IBAT, but the effects are more severe in B/6J mice than in A/J mice. Interestingly, these findings in B/6J mice are similar to our earlier observations in genetically obese (ob/ob) mice, with whom they share a common genetic background (14) .
Previous studies have shown that B/6J mice raised on a high fat diet develop insulin resistance and diabetes (4).
FIG. 7.
Adenylyl cyclase activity in epididymal WAT of A/J and B/6J mice consuming a high fat diet containing CL316,243. After the 16-week period on the high fat diet supplemented with 0.001% CL316,243, gonadal WAT was removed, and plasma membranes were prepared as previously described (13, 39) . ␤-Agonist-stimulated adenylyl cyclase activity was determined in response to increasing doses of epinephrine (A) or CL316,243 (B).
FIG. 8.
Adenylyl cyclase activity in interscapular BAT of A/J and B/6J mice consuming a high fat diet containing CL316,243. After the 16-week period on the high fat diet supplemented with 0.001% CL316,243, IBAT was removed, and plasma membranes were prepared as previously described (13, 39) . ␤-Agonist-stimulated adenylyl cyclase activity was determined in response to increasing doses of epinephrine (A) or CL316,243 (B).
Moreover, analysis of white adipocyte depots indicates that high fat-fed, obese, B/6J mice display both adipocyte hyperplasia and hypertrophy. By contrast, A/J mice gain less body weight, do not develop diabetes, and show adipocyte hypertrophy without hyperplasia (5, 7). Our current results lend support to the idea that adipocyte adrenergic function is critical in the pathophysiology of diet-induced obesity and type II diabetes in the B/6J model. The ability of B/6J mice to dramatically increase their feed efficiency (weight gain/ Cal consumed) is reminiscent of the "thrifty gene" hypothesis proposed by Neel 30 yr ago (34) . Neel noted that ob/ob mice were able to survive food restriction much better than other strains. He went on to hypothesize that the genes responsible for diabetes were thrifty genes that evolved because of their adaptive value in an environment where food was scarce. Our results suggest that these genes reside in the B/6J background of the ob/ob mouse, and that they may be related to the ability of these animals to store fat when it is plentiful.
Regulation of adipose tissue metabolism has been shown to be impaired in genetically obese animals. Most studies have focused on the C57BL/6J obese (ob/ob) mouse, in which it has been shown that ␤-adrenergic-stimulated lipolysis and cAMP production are significantly reduced (10 -12) . In earlier studies we reported that the expression and function of ␤ 1 AR and ␤ 3 AR are significantly depressed in adipose tissue of the ob/ob mouse (14) . The results presented here on dietinduced obesity further underscore the importance of these earlier findings. Although the A/J and B/6J mice studied in the current work do not possess specific genetic mutations, the results show that certain genetic backgrounds combined with the consumption of a high fat diet can result in a similar impairment in ␤-agonist-stimulated adenylyl cyclase activity (and decreased ␤AR expression).
A finding of major significance in these studies is that the ␤ 3 AR agonist, CL316,243, could prevent diet-induced obesity and hyperinsulinemia in A/J mice. In marked contrast, chronic treatment with this ␤ 3 AR agonist did not prevent obesity or diabetes in B/6J mice. Our data also demonstrate that CL316,243 completely prevented the loss in adipocyte ␤AR gene expression and function only in A/J mice. An equally revealing feature of these results is that only A/J mice showed substantial levels of UCP in such typical WAT depots as sc and gonadal fat. Thus, the effects of CL316,243 on weight may also be mediated by induction of brown adipocytes in WAT depots. This is consistent with observations of other investigators on the acute effects of CL316,243 treatment in rats (21) . The decrease in ␤ 3 AR mRNA levels that we observed in IBAT from animals treated with CL316,243 may be related to earlier studies by Granneman and colleagues (30) , in which they found that cold exposure (i.e. induction of active thermogenesis) led to a decrease in ␤ 3 AR mRNA in IBAT. However, the molecular basis for these results is not presently clear. As radioligands specific for ␤ 3 AR have not been developed, we do not know whether the level of ␤ 3 AR mRNA directly correlates with the amount of functional ␤ 3 AR protein in thermogenically active IBAT. For example, it is possible that upon stimulation of brown adipocytes, new ␤ 3 AR protein is synthesized in a process that leads to ␤ 3 AR mRNA degradation, similar to the translationcoupled degradation of c-myc mRNA (35, 36) . This situation would result in a greater amount of functional ␤ 3 AR protein and less ␤ 3 AR mRNA. Another issue that should be addressed is whether the coupling of ␤ 3 AR in thermogenically active IBAT is more efficient, such that each mole of receptor protein is capable of generating a greater number of moles of cAMP. There are also several different adenyl cyclase isozymes that are expressed in brown adipocytes (17) . Possibly, the expression of a particular form of adenylyl cyclase is increased during active recruitment of IBAT, again potentially leading to a greater turnover of ATP to cAMP per U ␤ 3 AR protein available. Experiments to examine these issues and other aspects of the regulation of the three ␤ARs in brown adipocytes should ultimately provide an explanation for our in vivo observations. An important aspect of our experiments and one that distinguishes them from other studies of ␤ 3 AR agonists in mice is that the effect of CL316,243 to prevent obesity in A/J mice, but not B/6J mice, persists throughout a chronic treatment regimen. Thus, genetic background appears to be a key determining factor in both the propensity to develop obesity and the appearance in B/6J mice of clinical features of noninsulin-dependent diabetes mellitus. Although the most clearly identified function of BAT depots in rodents and human neonates is related to thermoregulation (37), the ability to pharmacologically prevent obesity and simultaneously recruit BAT in typically WAT depots supports the results of other studies, which indicated a critical role of BAT in the regulation of body composition (31) (32) (33) .
In most human as well as rodent obesity, elevated levels of leptin are commonly found (38 -40) , and it has been suggested that a functional defect in the leptin receptor may exist, analogous to the diabetic (db/db) mutation in mice (41, 42) . We have recently reported that chronic ␤ 3 AR agonist Northern blot analyses measured the relative levels of UCP mRNA, corrected for expression of cyclophilin, as described in Materials and Methods and shown in Figure 9 . Each sample set was analyzed independently twice. *, P Ͻ 0.05; %, P Ͻ 0.001 (significantly greater than low fat-fed group).
treatment can decrease leptin levels in diet-induced obese A/J mice (29) , and that administration of recombinant leptin to ob/ob mice increases sympathetic outflow to IBAT (43) . In view of our new findings reported here that high fat feeding precipitates a defect in adrenergic control of adipocyte function, particularly in B/6J mice, we propose that the high leptin levels frequently observed in obesity represent the result of a fat-induced disruption in the normal feedback that regulates adipocyte function. For example, in B/6J mice, in which this fat-induced defect is more severe than in A/J mice, diet-induced obesity is consequently more pronounced. Given the overwhelming evidence that most human obesity is linked to high fat consumption (2, 3, 9) , it is likely that this mechanism plays an important role. Future studies that address the mechanism by which fat intake can lead to disruption of adipocyte adrenergic receptor function may, therefore, provide new insights into the pathophysiology of the most common forms of obesity.
